Diabetes Drug Fails As Add-On Therapy
Vitae-Boehring has reported that its diabetes drug failed to reduce blood sugar levels in several patients during clinical studies.
Details of the Failed Diabetes Drug
According to Reuters Health, Vitae Pharmaceuticals Incorporation has recently released word that its diabetes drug failed to significantly reduce blood sugar levels in the immune systems of several patients.
The drug was commonly used as an add-on therapy drug, but now officials are questioning the drug’s legitimacy. In connection to the failure of the drug, Vitae’s stock market shares plummeted as much as 34%.
The Vitae-Boehring combination diabetes drug, known scientifically as VTP-34072, was to be used as an add-on therapy drug alongside the common diabetes drug metformin and administered to overweight patients with type II diabetes. The drug is supposed to work to target the hormone cortisol, which is responsible for increasing blood sugar levels and breaking down fat in individuals.
The failure of the diabetes drug is yet another blow to Vitae this year after trials for a groundbreaking Alzheimer’s drug were put on hold back in February.
The following information was provided by the American Diabetes Association:
- Approximately 29.1 million Americans (9.3% of the U.S. population) have diabetes.
- It is estimated that 8.1 million Americans with diabetes are undiagnosed.
- Roughly 1.7 million new incidences of diabetes occur every year.
- Diabetes is the seventh leading cause of death in the United States.